A randomized, double-blind, placebo-controlled, parallel-group 12-week trial evaluating the safety and efficacy of the salmeterol/fluticasone propionate combination in GR106642X MDI, 50/250mcg BID, and salmeterol in propellant 11/12 MDI, 50mcg BID, fluticasone propionate in propellant 11/12 MDI, 250mcg BID, and placebo propellant GR106642X MDI in adult and adolescent subjects with asthma

Authors
Category Primary study
Registry of TrialsGSK Study Register
Year 2007
Study Period: December 1998 to March 2000. Study number SAS30004
Epistemonikos ID: f02ff36db24d758dfce0be27a72781341a266b17
First added on: Aug 21, 2024